Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Analysis of p73 in human borderline and invasive ovarian tumor

Abstract

p73 is a novel gene that has high sequence homology and similar gene structure to the tumor suppressor gene p53. We analysed p73 in seven ovarian carcinoma cell lines and a total of 63 human borderline and invasive ovarian tumor samples. Loss of heterozygosity at this locus was observed in 50% of invasive tumors but in none of the borderline tumors. Biallelic expression of the gene was observed in the heterozygous tumor tissues. Direct sequencing and single-strand conformation polymorphism analyses of the p73 cDNA sequence homologous to the highly mutatable region of p53 did not reveal any mutations. When compared to the primary cultures of normal human ovarian surface epithelial cells and immortalized cell lines, four of the seven ovarian carcinoma cell lines, 71% of the invasive tumors, and 92% of the borderline tumor tissues express elevated levels of p73 transcript. Except for the OVCA3 cell line, Western blot analysis of the nuclear extracts prepared from the cell lines showed concordant levels of p73 protein. Our analysis also demonstrated the expression of a spliced variant of p73 transcript with the omission of exon 2 solely in the cancer cell lines and invasive tumor tissues. This exon 2-spliced transcript would give rise to a truncated p73 protein without the N-terminal transactivation domain. In reminiscence of the dominant negative phenotype of the N-terminal truncated variants of another p53-related gene, p63, the expression of the truncated p73 variant form in ovarian tumors may play an important role in the pathogenesis of ovarian cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Chi SW, Ayed A and Arrowsmith CH . 1999 EMBO J 18: 4438–4445

  • Coles C, Condie A, Chetty U, Steel CM, Evans HJ and Prosser J . 1992 Cancer Res 52: 5291–5298

  • Davison TS, Vagner C, Kaghad M, Ayed A, Caput D and Arrowsmith CH . 1999 J Biol Chem 274: 18709–18714

  • Dobbelstein M, Wienzek S, Konig C and Roth J . 1999 Oncogene 18: 2101–2106

  • Fajac A, Benard J, Lhomme C, Rey A, Duvillard P, Rochard F, Bernaudin JF and Riou G . 1995 Int J Cancer 64: 146–151

  • Frankel RH, Bayona W, Koslow M and Newcomb EW . 1992 Cancer Res 52: 1427–1433

  • Hagiwara K, McMenamin MG, Miura K and Harris CC . 1999 Cancer Res 59: 4165–4169

  • Higashino F, Pipas JM and Shenk T . 1998 Proc Natl Acad Sci USA 95: 15683–15687

  • Jost CA, Marin MC and Kaelin Jr WG . 1997 Nature 389: 191–194

  • Kaghad M, Bonnet H, Yang A, Creancier L, Biscan J-C, Valent A, Minty A, Chalon P, Lelias J-M, Dumont X, Ferrara P, McKeon F and Caput D . 1997 Cell 90: 809–819

  • Kovalev S, Marchenko N, Swendeman S, LaQuaglia M and Moll UM . 1998 Cell Growth Differ 9: 897–903

  • Kubbutat MH, Jones SN and Vousden KH . 1997 Nature 387: 299–303

  • Mai M, Yokomizo A, Qian C, Yang P, Tindall DJ, Smith DI and Liu W . 1998 Cancer Res 58: 2347–2349

  • Marin MC, Jost CA, Irwin MS, DeCaprio JA, Caput D and Kaelin Jr WG . 1998 Mol Cell Biol 18: 6316–6324

  • Mok SC, Bell DA, Knapp RC, Fishbaugh PM, Welch WR, Muto MG, Berkowitz RS and Tsao SW . 1993 Cancer Res 53: 1489–1492

  • Mok SC, Kwok TT, Berkowitz RS, Barrett AJ and Tsui FWL . 1995 Gyn Oncol 57: 299–303

  • Nomoto S, Haruki N, Kondo M, Konishi H, Takahashi T, Takahashi T and Takahashi T . 1998 Cancer Res 58: 1380–1383

  • Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, Katoh I, Ikawa Y, Nimura Y, Nakagawara A, Obinata M and Ikawa S . 1998 Nat Med 4: 839–843

  • Pejovic T . 1995 Ann Med 27: 73–78

  • Schmale H and Bamberger C . 1997 Oncogene 15: 1363–1367

  • Shimada A, Kato S, Enjo K, Osada M, Ikawa Y, Kohno K, Obinata M, Kanamaru R and Ishioka C . 1999 Cancer Res 59: 2781–2786

  • Takahashi H, Ichimiya S, Nimura Y, Watanabe M, Furusato M, Wakui S, Yatani R, Aizawa S and Nakagawara A . 1998 Cancer Res 58: 2076–2077

  • Thompson FH, Taetle R, Trent JM, Liu Y, Massey-Brown K, Scott KM, Weinstein RS, Emerson JC, Alberts DS and Nelson MA . 1997 Cancer Genet Cytogenet 96: 106–110

  • Thut CJ, Goodrich JA and Tjian R . 1997 Genes Dev 11: 1974–1986

  • Trink B, Okami K, Wu L, Sriuranpong V, Jen J and Sidransky D . 1998 Nat Med 4: 747–748

  • Wertheim I, Muto MG, Welch WR, Bell DA, Berkowitz RS and Mok SC . 1994 J Natl Cancer Inst 86: 1549–1551

  • Yaginuma Y and Westphal H . 1992 Cancer Res 52: 4196–4199

  • Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Doetsch V, Andrews NC, Caput D and McKeon F . 1998 Mol Cell 2: 305–316

  • Yokomizo A, Mai M, Tindall DJ, Cheng L, Bostwick DG, Naito S, Smith DI and Liu W . 1999 Oncogene 18: 1625–1629

  • Zeng X, Chen L, Jost CA, Maya R, Keller D, Wang X, Kaelin Jr WG, Oren M, Chen J and Lu H . 1999 Mol Cell Biol 19: 3257–3266

Download references

Acknowledgements

We acknowledge the provision of p73 antibody from Dr Frank McKeon. This work was supported in part by NIH grants CA70216 (to S-W Ng) and R01CA69453, R01CA69291 and R01CA63381 (to SC Mok).

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ng, SW., Yiu, G., Liu, Y. et al. Analysis of p73 in human borderline and invasive ovarian tumor. Oncogene 19, 1885–1890 (2000). https://doi.org/10.1038/sj.onc.1203512

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203512

Keywords

This article is cited by

Search

Quick links